Skip to main content
AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited — Investor Relations & Filings

Ticker · AFT ISIN · NZAFTE0001S4 NZX Manufacturing
Open in API
Filings indexed 324 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country NZ New Zealand
Listing NZX AFT

About AFT Pharmaceuticals Limited

https://www.aftpharm.com

AFT Pharmaceuticals Limited focuses on the development, licensing, and distribution of pharmaceutical products across a broad range of therapeutic categories. The company’s core portfolio includes pain management, dermatology, eye care, and hospital-based medicines. Its flagship product, Maxigesic, is a patented combination of paracetamol and ibuprofen available in multiple dosage forms and marketed globally. AFT Pharmaceuticals emphasizes research and development to create innovative delivery systems and therapeutic solutions. The company operates through a combination of direct sales in specific regions and international licensing agreements, reaching markets in over 100 countries. Its product range spans over-the-counter (OTC) and prescription medications, targeting both retail pharmacy and clinical environments.

Recent filings

Filing Released Lang Actions
Annual Meeting and Closing Date for Director Nominations
Regulatory Filings Classification · 75% confidence The document is an announcement of the date, location, and nomination closing date for the upcoming Annual General Meeting. It does not contain AGM presentation materials or financial data, nor is it a proxy statement or formal Notice of Meeting with full materials. It is a general regulatory announcement regarding the company’s meeting schedule, so it falls under the catch-all Regulatory Filings category.
2026-05-24 English
issue of unlisted Options
Share Issue/Capital Change Classification · 90% confidence The document is a formal ‘Capital Change Notice’ filed on NZX, detailing the issuance of unlisted options (to acquire ordinary shares) under a long-term incentive plan, including specific terms, amounts, dates, and authority. It is clearly an announcement of new financial instruments issued (options), which falls under share issue/capital change filings.
2026-05-21 English
FY26 dividend distribution notice
Notice of Dividend Amount Classification · 90% confidence The document is titled “Distribution Notice” and provides detailed information on a final dividend: record date, ex-date, payment date, total monies, per‐share cash distribution, imputation credits, resident withholding tax, and related dividend mechanics. This is a formal announcement of dividend amount and distribution details. Therefore, it fits the Notice of Dividend Amount category.
2026-05-20 English
AFT delivers double digit revenue growth and record earning
Earnings Release Classification · 92% confidence The document is a press release announcing the company’s full‐year financial results for the year ended 31 March 2026, including key highlights (revenue growth, profit figures, dividends, outlook). It is not the full Annual Report (which is referenced separately) nor a detailed regulatory filing; it is the initial announcement of periodical financial results. Therefore it matches the definition of an Earnings Release (ER). FY 2026
2026-05-20 English
AFT Pharmaceuticals names Stuart Houliston CFO
Board/Management Information Classification · 90% confidence The document is a press release announcing the appointment of Stuart Houliston as Chief Financial Officer, replacing the retiring CFO and detailing changes in senior management. This clearly falls under a Board/Management Information announcement (management reshuffle).
2026-05-17 English
AFT to announce full year results on May 21 2026v
Regulatory Filings
2026-05-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.